CTI BioPharma Corp.
CTICNASDAQHealthcare
$9.10
+$0.01(+0.06%)
Market Cap$1.2B
P/E Ratio—
52W High$9.1
52W Low$4.01
CTI BioPharma Corp. (CTIC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CTIC · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 14, 2023EPS Actual
-$0.21
Est. -$0.08 · -162.5%
Revenue
—
Est. $0.03B
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 14, 2023
After Market Close
▼ Miss EPS
CTIC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | May 9, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 4, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 6, 2023 | — | — | — | — | — | — |
| ▼ Q3 FY2023 | Aug 14, 2023 | -$0.08 | -$0.21 | -162.5% | — | $0.03B | — |
| — Q2 FY2023 | May 15, 2023 | -$0.10 | -$0.10 | +0.0% | $0.02B | $0.02B | +5.1% |
| ▼ Q1 FY2023 | Mar 6, 2023 | -$0.09 | -$0.14 | -55.6% | $0.02B | $0.02B | -11.3% |
| ▲ Q4 FY2022 | Nov 7, 2022 | -$0.15 | -$0.13 | +13.3% | $0.02B | — | — |
| ▼ Q3 FY2022 | Aug 8, 2022 | -$0.20 | -$0.21 | -5.0% | $0.01B | — | — |
Q2 FY2024
May 9, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 4, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 6, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 14, 2023Miss
EPS Actual
-$0.21
EPS Est.
-$0.08
EPS Surpr.
-162.5%
Revenue
—
Q2 FY2023
May 15, 2023
EPS Actual
-$0.10
EPS Est.
-$0.10
EPS Surpr.
+0.0%
Revenue
$0.02B
Q1 FY2023
Mar 6, 2023Miss
EPS Actual
-$0.14
EPS Est.
-$0.09
EPS Surpr.
-55.6%
Revenue
$0.02B
Q4 FY2022
Nov 7, 2022Beat
EPS Actual
-$0.13
EPS Est.
-$0.15
EPS Surpr.
+13.3%
Revenue
$0.02B
Q3 FY2022
Aug 8, 2022Miss
EPS Actual
-$0.21
EPS Est.
-$0.20
EPS Surpr.
-5.0%
Revenue
$0.01B
No analyst estimates available for CTIC.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2023 | Aug 14, 2023 | -162.5% | $9.09 | — | — |
| ▲ Q2 FY2023 | May 15, 2023 | +0.0% | $8.96 | $8.93 | -0.33% |
| ▼ Q1 FY2023 | Mar 6, 2023 | -55.6% | $5.38 | $4.83 | -10.22% |
| ▲ Q4 FY2022 | Nov 7, 2022 | +13.3% | $5.34 | $4.97 | -6.93% |
| ▼ Q3 FY2022 | Aug 8, 2022 | -5.0% | $7.43 | $7.06 | -4.98% |
| ▼ Q2 FY2022 | May 12, 2022 | -5.7% | $3.55 | $3.66 | +3.10% |
| — Q4 FY2021 | Dec 31, 2021 | — | $2.48 | $2.48 | +0.00% |
| ▼ Q4 FY2021 | Nov 12, 2021 | -18.2% | $2.53 | $2.67 | +5.53% |
Q3 FY2023—
Report Date
Aug 14, 2023
EPS Beat/Miss
-162.5%
Price Before
$9.09
Price After
—
Q2 FY2023-0.33%
Report Date
May 15, 2023
EPS Beat/Miss
+0.0%
Price Before
$8.96
Price After
$8.93
Q1 FY2023-10.22%
Report Date
Mar 6, 2023
EPS Beat/Miss
-55.6%
Price Before
$5.38
Price After
$4.83
Q4 FY2022-6.93%
Report Date
Nov 7, 2022
EPS Beat/Miss
+13.3%
Price Before
$5.34
Price After
$4.97
Q3 FY2022-4.98%
Report Date
Aug 8, 2022
EPS Beat/Miss
-5.0%
Price Before
$7.43
Price After
$7.06
Q2 FY2022+3.10%
Report Date
May 12, 2022
EPS Beat/Miss
-5.7%
Price Before
$3.55
Price After
$3.66
Q4 FY2021+0.00%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$2.48
Price After
$2.48
Q4 FY2021+5.53%
Report Date
Nov 12, 2021
EPS Beat/Miss
-18.2%
Price Before
$2.53
Price After
$2.67
Avg Beat Reaction-3.63%
Avg Miss Reaction-1.64%
Beat Rate2 / 8 quarters
Largest Move-10.22% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CTIC ends December
CTI BioPharma Corp. (CTIC) most recently reported earnings on August 14, 2023 for Q3 FY2023, posting EPS of $-0.21 — missing the analyst consensus of $-0.08 by -162.5%. The next CTIC earnings date is expected around September 1, 2026.
Each quarter, investors track CTIC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CTIC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CTIC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CTIC earnings · 5 questionsCTI BioPharma Corp.'s next earnings report is expected around September 1, 2026. CTIC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CTIC historically reports after market close (AMC).
CTIC earnings datewhen is CTIC earningsCTIC next earnings datewhen does CTIC report earningsCTIC earnings calendar
▸ Source: FMP · CTI BioPharma Corp. SEC filings · US GAAP · CTI BioPharma Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026